Osiris Therapeutics (OSIR) researches, develops, manufactures, markets, and distributes regenerative medicine products.
OSIR products include Grafix, a cryopreserved placental membrane for treating hard-to-treat acute and chronic wounds, venous leg ulcers, and burns; BIO4, a bone allograft for use in all surgical applications, including spine, trauma, extremity, cranial, and foot and ankle surgery; and Cartiform, a viable chondral allograft that promotes articular cartilage repair to treat focal chondral defects.
Osiris Therapeutics, Inc. was founded in 1992 and is headquartered in Columbia, Maryland.
October 28, 2019
RegMed Investors’ (RMi) closing bell: indexes set new records
October 26, 2019
RegMed Investors’ (RMi) closing bell: the oversold are flirting with the upside and it ain’t a love match
October 24, 2019
RegMed Investors’ (RMi) closing bell: Low volume and percentage moves do not glamorize the sector for short-term investment
October 23, 2019
RegMed Investors’ (RMi) closing bell: the ceiling hasn’t fallen yet, the leaks are increasing
October 22, 2019
RegMed Investors’ (RMi) closing bell: downward motion follows yesterday’s upswing
October 21, 2019
RegMed Investors’ (RMi) closing bell: sector equities are along for the ride with market indexes
October 18, 2019
RegMed Investors’ (RMi) closing bell: escaping the maze of the oversold
October 17, 2019
RegMed Investors’ (RMi) closing bell: three (3) up sessions and counting
October 16, 2019
RegMed Investors’ (RMi) closing bell: low volume and minimal percentage moves
October 15, 2019
RegMed Investors’ (RMi) closing bell: the oversold were on the road to a comeback
35 companies, 1 interpreter!
Insight, foresight and recommendation
Osiris Therapeutics (OSIR) – Late Filing, SEC issues, officer crimminal indictments and yet another COO departs (number 5 in four years?). Started the year 2018 at $6.15, dived and jived to $6.95 by 2/1 and achieved $9.08 by 2/21. Once their "clean" it will be worth a near term topic until then "play" monopoly with the shares ... NO trust
holdMy motto … never leave an investor uninformed! I say today what others won’t, so you can do what others can’t.
My name is Henry McCusker; I endorse these opinions under my own name and with a subscription based membership.
Do you have an opinion you would like to share with us? We would like to hear from you.
Please e-mail us at hwm@regmedinvestors.com.
Editor and Publisher ... Henry McCusker enters his tenth (10th) year at RegMed Investors